NRX Pharmaceuticals (NRXP) Non-Current Debt (2018 - 2021)
NRX Pharmaceuticals (NRXP) posted quarterly Non-Current Debt of $1.4 million for Q1 2021, down 15.43% year-over-year from $1.6 million in Q1 2020, and up 82.04% quarter-over-quarter from $758060.0 in Q3 2020.
NRX Pharmaceuticals (NRXP) Non-Current Debt (2018 - 2021) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Non-Current Debt for 4 consecutive years, with $1.4 million the latest figure, recorded in Q1 2021.
- In Q1 2021, Non-Current Debt fell 15.43% year-over-year to $1.4 million; the TTM figure through Mar 2021 stood at $1.4 million (down 15.43% YoY), while the FY2019 annual figure was $416141.0, down 39.69% from the prior year.
- Non-Current Debt rose to $1.4 million in Q1 2021 per NRXP's latest filing, from $758060.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.7 million in Q2 2020 and bottomed at $327198.0 in Q3 2019.
- Historically, Non-Current Debt has averaged $1.1 million across 4 years, with a median of $1.4 million in 2019.
- Annual changes were most pronounced in 2019 — Non-Current Debt tumbled 39.69% — and 2020, when it soared 131.68%.
- NRX Pharmaceuticals' Non-Current Debt stood at $690000.0 in 2018, then sank by 39.69% to $416141.0 in 2019, then soared by 82.16% to $758060.0 in 2020, then soared by 82.04% to $1.4 million in 2021.
- Business Quant data shows NRXP's Non-Current Debt at $1.4 million in Q1 2021, $758060.0 in Q3 2020, and $1.7 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 1.38 Mn |
| Sep 30, 2020 | 758,060.00 |
| Jun 30, 2020 | 1.67 Mn |
| Mar 31, 2020 | 1.63 Mn |
| Dec 31, 2019 | 416,141.00 |
| Sep 30, 2019 | 327,198.00 |
| Jun 30, 2019 | 1.38 Mn |
| Mar 31, 2019 | 1.49 Mn |
| Dec 31, 2018 | 690,000.00 |